In fact, the TRAIL-R2xCD3 BsAb that we had developed, despite poor ability to activate the extrinsic apoptotic pathway as well when multimerized by crosslinkers, was able to efficiently redirect activated T-cells and led to killing of TRAIL-R2+ tumor cells by perforin and granzyme. The gene discussed is PRF1; the disease is neoplasm.